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Abstract: Pseudomonas aeruginosa is a major cause of chronic lung infections in cystic fibrosis (CF)
patients. The ability of the bacterium to form biofilms and the presence of a thick and stagnant
mucus in the airways of CF patients largely contribute to antibiotic therapy failure and demand
for new antimicrobial agents able to act in the CF environment. The present study investigated the
anti-P. aeruginosa activity of lin-SB056-1, a recently described semi-synthetic antimicrobial peptide,
used alone and in combination with the cation chelator ethylenediaminetetraacetic acid (EDTA).
Bactericidal assays were carried out in standard culture conditions and in an artificial sputum
medium (ASM) closely resembling the CF environment. Peptide’s structure and interaction with large
unilamellar vesicles in media with different ionic strengths were also investigated through infrared
spectroscopy. Lin-SB056-1 demonstrated fast and strong bactericidal activity against both mucoid
and non-mucoid strains of P. aeruginosa in planktonic form and, in combination with EDTA, caused
significant reduction of the biomass of P. aeruginosa mature biofilms. In ASM, the peptide/EDTA
combination exerted a strong bactericidal effect and inhibited the formation of biofilm-like structures
of P. aeruginosa. Overall, the results obtained highlight the potential of the lin-SB056-1/EDTA
combination for the treatment of P. aeruginosa lung infections in CF patients.
Keywords: Pseudomonas aeruginosa; cystic fibrosis; antimicrobial peptide; artificial sputum medium;
biofilm; infrared spectroscopy
1. Introduction
Cystic fibrosis (CF) is a genetically inherited disease characterized by defects in the transport
protein cystic fibrosis transmembrane conductance regulator (CFTR), causing the production of
a sticky mucus that stands in the respiratory tract [1]. Consequently, CF patients display a very
high susceptibility to chronic lung infections that represent an important cause of morbidity and
mortality associated with the disease [2]. Pseudomonas aeruginosa is the leading cause of lung infections
and a primary cause of death in CF patients [2]. During the course of the infection, adaptation
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of P. aeruginosa to lung environment involves the shift from a non-mucoid to a mucoid phenotype
that has been associated with a worse clinical prognosis [3]. Conversion to a mucoid phenotype
implies the overproduction of the polysaccharide alginate, which protects P. aeruginosa from the
action of the currently available drugs and confers a selective advantage to the bacterium in the
CF lung [3]. Moreover, a major factor contributing to the development of persistent infection is the
formation of a biofilm, a well-known virulence factor of P. aeruginosa that renders bacteria recalcitrant
to host immune response and antibiotic treatment. Traditionally, bacterial biofilms are referred to
as surface-attached communities of bacteria encased within a self-produced extracellular matrix of
complex composition [4]. It is now recognized that P. aeruginosa biofilms in the CF airway possess
peculiar features. Instead of the classical surface-attached communities, detected in most biofilm
infections, in the CF airway, P. aeruginosa forms biofilms composed of small clusters of planktonic
bacterial aggregates containing dead neutrophils [5]. These non-attached cell aggregates, referred to
as biofilm-like structures (BLS), appear to share many properties with conventional surface-attached
biofilms, including dependence on quorum sensing, presence of subpopulations of dormant cells
(“persisters”), and resistance to antibiotics [6].
The CF lung environment is characterized by the presence of abundant sputum that contains
mucin, lipids, proteins, amino acids, ions and DNA released by dead neutrophils and promotes
bacterial colonization [7,8]. Extracellular DNA contributes to render the sputum highly viscous by
forming a gel-like matrix with other macromolecules that affects lung function and antibiotic efficacy.
Once P. aeruginosa has established a chronic infection, it is hardly eradicated [9]. Therefore, there is
a critical need for novel antimicrobial drugs that can effectively suppress bacterial infections in the
challenging environment of the CF lung.
Over the last several decades, antimicrobial peptides (AMPs) have been intensely investigated as
potential antibiotics against multidrug resistant bacteria [10]. Most AMPs are cationic molecules with
an amphipathic structure as a consensus motif for antimicrobial activities that selectively target the
membranes of bacteria via electrostatic forces. In contrast to standard antibiotics, AMPs are effective
against both quiescent and actively growing bacteria, as they generally do not require metabolic
processes for antimicrobial activity, display rapid killing kinetics, and demonstrate low propensity
to select resistant mutants in vitro [11]. In recent years, the possible use of AMPs against microbial
biofilms has been largely highlighted, as it appears that such molecules display several properties
considered beneficial to prevent/eradicate biofilms [12–14].
We recently described an optimized semi-synthetic antimicrobial peptide called lin-SB056-1 [15].
Such a peptide has a β-type conformation and displays a perfect pattern of alternating hydrophilic
and hydrophobic residues in its primary structure. This high intrinsic amphipathicity of the peptide
induces a high structural stability of the peptide β-sheet oligomers on the membrane surfaces. These
structural properties confer lin-SB056-1 a strong antimicrobial activity [16].
The biofilm mode of growth, together with lung mucus viscosity, reduces the effectiveness of
conventional antibiotic therapy in CF [17]. Thus, the usage of adjuvants in CF therapy regimen has
been proposed to improve the diffusion of antimicrobials [18]. Different studies have shown that the
divalent cation chelator ethylenediaminetetraacetic acid (EDTA) can destabilize the biofilm structure by
interfering with the ionic attractive forces among the biofilm matrix components [19–21]. Furthermore,
EDTA is endowed with its own antimicrobial properties and has shown ability to potentiate the activity
of conventional antibiotics against biofilms of a variety of clinical strains [22].
In the present study, we evaluated the antimicrobial and antibiofilm activity of the peptide
lin-SB056-1, used alone and in combination with disodium-EDTA, in standard culture conditions
as well as in an artificial sputum medium (ASM) that closely mimics the thick and stagnant airway
mucus of CF patients. The structural determinants that drive the interaction of lin-SB056-1 with its
target membranes were also explored. A rapid and strong bactericidal activity of the peptide/EDTA
combination against planktonic cells as well as preformed biofilms of P. aeruginosa was demonstrated
in standard conditions. When assayed in ASM, the peptide in combination with host-compatible
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concentrations of disodium-EDTA was able to kill both mucoid and non-mucoid strains of P. aeruginosa
at relatively low concentrations and to almost completely inhibit the formation of BLS at non-hemolytic
concentrations. Analysis of the modes of interaction of lin-SB056-1 with lipid vesicles mimicking
bacterial membrane, performed using infrared spectroscopy as preferential biophysical technique,
revealed that the peptide activity enhancement in the presence of EDTA appears not to be correlated
with significant structural changes. This leads to hypothesize that the observed increased activity in
the presence of EDTA might be due to the ability of such chelator to sequester membrane-associated
divalent cations, thus probably synergizing with the peptide in perturbing membrane integrity.
Overall, the results obtained suggest that the lin-SB056-1/EDTA combination may represent an
attractive candidate to develop a new antimicrobial tool for the treatment of P. aeruginosa pulmonary
infections in CF patients.
2. Results
2.1. Bactericidal Activity and Killing Kinetics of Lin-SB056-1 against Planktonic Cells of Mucoid and
Non-Mucoid Strains of P. aeruginosa, in Sodium Phosphate Buffer (SPB) with 1% Tryptone Soya Broth (TSB)
To investigate the bactericidal activity of lin-SB056-1 against P. aeruginosa, minimal bactericidal
concentrations (MBCs) of the peptide towards three non-mucoid and three mucoid strains were
determined (Table 1). Remarkably, the peptide was bactericidal against all the tested strains at
relatively low concentrations ranging between 1.56 and 3.12 µg/mL. Interestingly, the bactericidal
concentrations against mucoid strains of P. aeruginosa were equal or even lower than those recorded
against non-mucoid strains.
Table 1. Antibiotic resistance profile of P. aeruginosa strains used in the study and their susceptibility to
lin-SB056-1 peptide in Sodium Phosphate Buffer (SPB) pH 7.4, 1% Tryptone Soya Broth (TSB).
Strain Phenotype Resistance Profile 1 MBC 2
ATCC 27853 Non-mucoid None 3.12
PaNM01 Non-mucoid FOS 3.12
PaNM02 Non-mucoid FOS 3.12
PaM01 Mucoid AMC-AZT-CIP-CTX-ERT-LVX-SAM-TIG-TOB 1.56
PaM02 Mucoid AMK-CIP-FEP-FOS-GEN-LVX-TOB 1.56
PaM03 Mucoid FOS-LVX-TOB 3.12
1 AMC: amoxicillin; AZT: azithromycin; AMK: amikacin; FOS: fosfomycin; CIP: ciprofloxacin; CTX: cefotaxime;
ERT: ertapenem; FEP: cefepime; GEN: gentamycin; LVX: levofloxacin; SAM: ampicillin-subactam; TIG: tigecycline;
TOB: tobramycin; 2 MBC: minimal bactericidal concentrations expressed in µg/mL.
Next, killing kinetics of the peptide at its MBCs were performed against P. aeruginosa ATCC 27853
and PaM01, representative of non-mucoid and mucoid strains, respectively. As shown in Figure 1a,b,
lin-SB056-1 exhibited very fast killing kinetics against both P. aeruginosa strains, reducing the bacterial
inoculum by three-log within 5 min of incubation.
2.2. Synergistic Activity of Lin-SB056-1 in Combination with EDTA on Preformed Biofilms of Mucoid and
Non-Mucoid Strains of P. aeruginosa
It is well recognized that the treatment of preformed biofilms is particularly challenging and
that combinations of molecules targeting different biofilm components are needed to improve the
therapeutic outcome [23]. Therefore, we tested the activity of lin-SB056-1 in combination with EDTA,
a cation chelator known to destabilize the biofilm structure and favor the antimicrobial activity of
conventional antibiotics as well as AMPs [22,24]. Established biofilms of two strains of P. aeruginosa
(one non-mucoid and one mucoid) were exposed to various concentrations of lin-SB056-1 or EDTA,
used alone or combined together, and the biofilm biomass was evaluated by crystal violet staining
after 24 h. The results of the most powerful combinations are shown in Figure 2.
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Figure 1. Time kill curves of lin-SB056-1 at its bactericidal concentrations against: (a) P. aeruginosa 
ATCC 27853; and (b) P. aeruginosa PaM01 in 10 mM Sodium Phosphate Buffer (SPB) at pH 7.4 
supplemented with 1% Tryptone Soya Broth (TSB). The concentrations of lin-SB056-1 (reported in 
parenthesis) are expressed in μg/mL. Control (CTRL) represents bacteria incubated in the absence of 
the peptide. Bactericidal activity was defined as a reduction in the numbers of viable bacteria of 
≥3-log colony forming units (CFU)/mL at any incubation time tested. The dotted lines represent 
three-log reduction in CFU number, corresponding to the definition of bactericidal activity. Data are 
reported as mean ± standard error of the mean of three independent experiments. 
 
Figure 2. Activity of lin-SB056-1, used alone and in combination with EDTA, against preformed 
biofilms of P. aeruginosa: (a) ATCC 27853; and (b) PaM01 strain. The antibiofilm activity of the 
peptide, EDTA and peptide-EDTA combination was evaluated by crystal violet staining after 24 h of 
incubation. The concentrations of lin-SB056-1 and EDTA (reported in parenthesis) are expressed in 
μg/mL and mM, respectively. Control (CTRL) represents bacteria incubated in the absence of 
antimicrobial agents; comb: peptide/EDTA combination. Data are reported as mean ± standard error 
of the mean of three independent experiments. ** p < 0.01, *** p < 0.001 (one way analysis of variance 
[ANOVA] followed by Tukey–Kramer post-hoc test). 
When lin-SB056-1 at 12.5 μg/mL and EDTA at 1.25 mM were used alone, no effect on mature 
biofilms of the non-mucoid strain P. aeruginosa ATCC 27853 was observed (Figure 2a). In contrast, 
the combinations of the two agents caused a reduction of more than 50% of the biofilm biomass of 
the same strain, as compared to the control biofilm. Similar results were obtained when the peptide 
was used at 25 μg/mL. The peptide used alone at 25 μg/mL was quite active against mature biofilms 
of the mucoid strain PaM01, reducing the biofilm biomass of such strain by 55% after 24 h incubation 
(Figure 2b). In agreement with the dependence on calcium to produce appreciable amount of biofilm 
by the mucoid strain PaM01 (see Section 4.5), established biofilms of such strain were also highly 
susceptible to relatively low concentrations of EDTA (0.6 mM, Figure 2b). Finally, when the peptide 
(25 μg/mL) and EDTA (0.6 mM) were combined together, the reduction of biofilm biomass of the 
PaM01 strain reached 80% as compared to the untreated control. 
.
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Figure 2. Activity of lin-SB056-1, used alone and in combination with EDTA, against preformed
biofilms of P. aeruginosa: (a) ATCC 27853; and (b) PaM01 strain. The antibiofilm activity of the peptide,
EDTA and peptide-EDTA combination was evaluated by crystal violet staining after 24 h of incubation.
The concentrations of lin-SB056-1 and EDTA (reported in parenthesis) are expressed in µg/mL and
mM, respectively. Control (CTRL) represents bacteria incubated in the absence of antimicrobial agents;
comb: peptide/EDTA combination. Data are reported as mean ± standard error of the mean of three
independent experiments. ** p < 0.01, *** p < 0.001 (one way analysis of variance [ANOVA] followed by
Tukey–Kramer post-hoc test).
When lin-SB056-1 at 12.5 µg/mL and EDTA at 1.25 mM were used alone, no effect on mature
biofilms of the non-mucoid strain P. aeruginosa ATCC 27853 was observed (Figure 2a). In contrast, the
combinations of the two agents caused a reduction of more than 50% of the biofilm biomass of the
same strain, as compared to the control biofilm. Similar results were obtained when the peptide was
used at 25 µg/mL. The peptide used alone at 25 µg/mL was quite active against mature biofilms of
the mucoid strain PaM01, reducing the biofilm biomass of such strain by 55% after 24 h incubation
(Figure 2b). In agreement with the dependence on calcium to produce appreciable amount of biofilm
by the mucoid strain PaM01 (see Section 4.5), established biofilms of such strain were also highly
susceptible to relatively low concentrations of EDTA (0.6 mM, Figure 2b). Finally, when the peptide
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(25 µg/mL) and EDTA (0.6 mM) were combined together, the reduction of biofilm biomass of the
PaM01 strain reached 80% as compared to the untreated control.
2.3. Bactericidal Effect of Lin-SB056-1 in Combination with EDTA against Planktonic P. aeruginosa in
Artificial Sputum Medium (ASM)
The accumulation of a thick and stagnant mucus in the airways of CF patients provides a suitable
environment for the persistence of P. aeruginosa within the lung of such patients. Thus, to explore the
peptide’s potential to exert anti-Pseudomonas activity in such environment, we tested the bactericidal
activity of lin-SB056-1 against P. aeruginosa ATCC 27853 and the mucoid strain PaM01 in ASM that
closely mimics the composition of CF sputum. Although lin-SB056-1 used at 12.5 µg/mL was inactive in
ASM 80% against both the ATCC 27853 and the PaM01 strains, the peptide showed a strong synergistic
effect when used in combination with 1.25 mM EDTA (Figure 3). In particular, the peptide/EDTA
combination caused a reduction of four-log of the colony forming units (CFU) number of the ATCC
strain (p < 0.001, Figure 3a), while, when tested against the mucoid strain PaM01, the combination
reduced the bacterial inoculum by 1.5-log (p < 0.001, Figure 3b).
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Bactericidal assays were also performed at 24 h against the ATCC 27853 strain. The results 
obtained (Figure S1) showed that at such incubation time the combination was also able to cause a 
statistically significant reduction of CFUs (approximately two-log) as compared to EDTA and 
lin-SB056-1 used alone. 
Finally, to get further insights on the activity of lin-SB056-1 in in vivo-like conditions, 
bactericidal assays were performed in the presence of 12.5% serum, as it may represent a component 
of the lung microenvironment during chronic infection/inflammation. As shown in Figure S2, 
lin-SB056-1, at the concentration of 12.5 μg/mL, exerted a very strong bactericidal effect against the 
ATCC 27853 strain at both 1.5 and 24 h. 
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It has been previously reported that P. aeruginosa growth in ASM resembles bacterial growth 
during lung infection of CF patients, with the formation of self-aggregating BLS [8]. To obtain BLS, 
P. aeruginosa ATCC 27853 was cultured in ASM in microaerophilic atmosphere and in static 
conditions for 72 h. An almost two-log increase in the number of P. aeruginosa cells was observed at 
the end of the incubation period as compared to the inoculum, demonstrating that the artificial 
medium was able to support bacterial growth (CTRL, Figure 4d). Furthermore, the conditions 
adopted also allowed P. aeruginosa to form cell-aggregates easily visible under light microscope at 
400× or 1000× magnification (Figure 4a,b). Using this experimental system, we evaluated the ability 
of the lin-SB056-1/EDTA combination to inhibit the formation of BLSs over the time. As shown in 
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aeruginosa ATCC 27853; and (b) P. aeruginosa PaM01 strain in ASM 80% after 1.5 h of incubation. The
concentrations of lin-SB056-1 and EDTA (reported in parenthesis) are expressed in µg/mL and mM,
respectively. Control (CTRL) represents bacteria incubated in the absence of antimicrobial agents;
comb: peptide/EDTA combination. Data are reported as mean ± standard error of the mean of three
independent experi ents. *** p <0.001 (one way ANOVA followed by Tukey–Kramer post-hoc test).
Bactericidal assays were also performed at 24 h against the ATCC 27853 strain. The results
obtained (Figure S1) showed that at such incubation time the combination was also able to cause
a statistically significant reduction of CFUs (approximately two-log) as compared to EDTA and
lin-SB056-1 used alone.
Finally, to get further insights on the activity of lin-SB056-1 in in vivo-like conditions, bactericidal
assays were performed in the presence of 12.5% serum, as it may represent a component of the lung
microenvironment during chronic infection/inflammation. As shown in Figure S2, lin-SB056-1, at the
concentration of 12.5 µg/mL, exerted a very strong bactericidal effect against the ATCC 27853 strain at
both 1.5 and 24 h.
2.4. Activity of Lin-SB056-1 in Combination with EDTA in Preventing the Formation of Biofilm-Like
Structures (BLSs) of P. aeruginosa ATC 27853 in ASM
It as bee previ sl re rt t t . aeruginosa gro th in S rese bles bacterial gro t
ri l i f ti of CF patients, with the formation of self-ag regating BLS [8]. To obtain
BLS, P. aeruginosa ATCC 27853 was c ltured in ASM in microaerophilic atmosphere i static
c iti f r . n al ost two-log increase in the number of P. aeruginosa cells was observed
at th end of the incubation period as compared to t i l , tr ti t t t artificial
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medium was able to support bacterial growth (CTRL, Figure 4d). Furthermore, the conditions adopted
also allowed P. aeruginosa to form cell-aggregates easily visible under light microscope at 400× or
1000× magnification (Figure 4a,b). Using this experimental system, we evaluated the ability of the
lin-SB056-1/EDTA combination to inhibit the formation of BLSs over the time. As shown in Figure 4c,
the peptide used at 12.5 µg/mL in combination with 1.25 mM EDTA was able to almost completely
inhibit the formation of BLS for the full length of the experiment (72 h). The number of viable
P. aeruginosa cells cultivated in ASM was also assessed at time 0 and at 1-day intervals in the presence
of lin-SB056-1, EDTA or both components. As shown in Figure 4d, a marked reduction in bacterial cell
number (almost three-log as compared to the untreated control) was observed at 24 h in the presence
of the peptide/EDTA combination. At later time points, the viable count progressively increased,
reaching levels similar to the control, after 72 h of incubation. No evident effect on CFU number was
observed when EDTA and lin-SB056-1 were used alone.
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intense component below 1620 cm−1 and the so-called secondary one at ~1680 cm−1 are characteristic
for β-sheets formation, in agreement with the literature on this model peptide [29]. The large separation
between the two amide I components is typical of antiparallel β-sheets [27,28]. The amide I band
profile of lin-SB056-1 (Figure 5) was comparable to that of KIGAKI, with only slight differences in the
position of the main component. On the other hand, significant differences were observed on the low
wavenumber side of the amide I (1590–1580 cm−1), where the significantly higher absorption in the
case of lin-SB056-1 is mostly due to guanidine group from arginine side chains, absent in KIGAKI.
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Signal/noise (S/N) ratio is usually good in RF spectra. However, whenever possible, it is advisable
to also inspect the corresponding spectra acquired from fully hydrated (FH) samples that represent
the more physiological condition of fully hydration [28,30–32]. Figure 6 shows the results for both
lin-SB056-1 and KIGAKI. Despite the lower S/N ratio, FH spectra confirm that lin-SB056-1 forms
β-sheets on top of both of the differently charged vesicles used in the present study. When compared to
RF spectra, a higher contribution from both random and turn components is clearly visible in the amide
I band between 1660 and 1640 cm−1, despite β-sheets components still dominate the amide I band.
The proportion of such unordered contributions is higher in lin-SB056-1 than KIGAKI. Interestingly,
both peptides showed a significant increase of structure order when moving from 25 to 75%mol.
1-palmitoyl-2-oleoyl-sn-glycero- 3-phospho-(1’-rac-glycerol) (POPG) vesicles (unordered components
decreased in relative intensity, Figure 6).
To investigate the influence of ionic strength on structure order, or the effect of possible direct
coordination of the peptide’s positive groups, lin-SB056-1 was also analyzed in the presence of 25%mol
POPG vesicles but using PB (low ionic strength) or PBS supplemented with EDTA instead of the
standard PBS. Figure 7 shows the amide I region of the infrared spectrum acquired both from RF
and FH samples. No significant differences are observed between spectra acquired in PBS and PB.
In the presence of EDTA, a significant proportion of random/turn contribution is observed in the RF
spectrum (Figure 7a), which is also visible (although to a lesser grade) in the FH spectrum despite the
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higher S/N (Figure 7b). In addition, both spectra show a difference in the guanidine group vibration
(1590–1580 cm−1). These results suggest that EDTA interacts with peptide positive side chains and
disturbs the formation of regular and extended β-sheets, at least in RF samples. However, in the
corresponding FH samples, which reflect a more physiological condition, differences with respect to
the spectrum acquired in the absence of EDTA are less pronounced, and overall the observed spectrum
is still compatible with a β-sheet structure (Figure 7b).Int. J. Mol. Sci. 2017, 18, 1994 8 of 18 
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3. Discussion
The development of resistance to currently available antibiotics by pathogens involved in
respiratory infections of CF patients is an issue causing increasing concern [33]. In particular, it is
reported that about one-half of patients with CF are stably colonized with multidrug-resistant (MDR)
P. aeruginosa [34]. To date, advancements in antimicrobial treatments of chronic P. aeruginosa infections
in CF patients mainly rely on the use of aerosolized antibiotic formulations [35]. Although inhalation
of antibiotics allows reaching high concentrations of the drugs directly in the lung, antimicrobial
resistance can still develop as an inevitable consequence of the repeated antibiotic use needed to treat
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acute exacerbations or to lower the bacterial burden of chronically colonized patients [35]. As novel
anti-Gram-negative antibiotics are scarce in the developmental pipeline and the therapeutic options
for multidrug-resistant P. aeruginosa infections are limited, the identification and pre-clinical testing of
new molecules with therapeutic potential is of paramount importance.
In this scenario, the interest in the use of AMPs as antimicrobials for the treatment of CF infections
has increased considerably and many different AMPs have been tested in in vitro and in vivo models
of CF infections with promising results [36–38]. As AMP activity against bacterial membranes is
less specific than that of many conventional antibiotics, the risk of developing bacterial resistance to
AMPs is considered low even after prolonged therapies. In addition, AMPs are often active against
MDR strains and, unlike other peptide-based antibiotics currently in clinical use (e.g., colistin and
daptomycin), exhibit a broad-spectrum of antibacterial activity. This latter property could be favorable
for the treatment of pulmonary mixed infections that often occur in CF patients. Furthermore, although
often highly inhibited in biological fluids [39], AMPs can be optimized by chemical modifications that
improve their stability and activity and lower their toxic potential in physiological conditions [15,40].
In this regard, we have previously described a semi-synthetic AMP, SB056, identified by selecting
a random phage library against whole Escherichia coli cells [41]. An analog of SB056 with improved
amphipathic profile, lin-SB056-1 (KWKIRVRLSA), was obtained by exchanging the position of the first
two residues of the original sequence but leaving the rest absolutely unchanged, net positive charge
included. This simple modification proved to have deep consequences on the biological properties
of the optimized peptide, which displayed significantly stronger activity against both Gram-positive
and Gram-negative bacteria, in particular when tested in broth supplemented with physiological
concentration of electrolytes [15,16].
In the first part of the present study, we demonstrated that lin-SB056-1 is highly active against
both mucoid and non-mucoid P. aeruginosa strains, irrespective of their resistance phenotype. The shift
towards a mucoid phenotype and the consequent overproduction of alginate is regarded to play a
pivotal role in chronic P. aeruginosa infections, as alginate renders P. aeruginosa strains more tolerant to
antibiotics [42]. Importantly, we found that the bactericidal concentrations of lin-SB056-1 against the
mucoid strains of P. aeruginosa were similar or even lower than those recorded against non-mucoid
strains. This suggests that the peptide is able to penetrate the alginate barrier and interact with its
bacterial target(s). The peptide was not only bactericidal at relatively low concentrations, but also
showed a very rapid killing effect (within 5 min) towards representative non-mucoid and mucoid
strains of P. aeruginosa. This rapid killing time is compatible with a membrane-perturbing mechanism
of action, in agreement with previous observations showing that the formation of extended β-sheets
leads to an enhanced antimicrobial activity of lin-SB056-1 causing a marked alteration of membrane
integrity [16].
Infrared spectroscopy analysis of the interaction of lin-SB056-1 with lipid vesicles mimicking
bacterial membrane confirmed the tendency of the peptide to form β-sheets on top of the charged
vesicles used in the present study, with an increase in structure order as the experimental system shifted
from a lower to a higher percentage of charged lipids. The formation of β-sheets was also verified by
comparison with the behavior of the well-characterized model peptide KIGAKI, and was retained even
at physiological salt concentration (PBS). In the presence of EDTA, recorded RF spectrum indicates that
EDTA interacts with peptide positive side chains and disturbs the formation of regular and extended
β-sheets. However, in the FH spectrum, which reflects a more physiological condition, differences
with respect to the spectrum acquired in the absence of EDTA are less pronounced, and overall the
observed spectrum is still compatible with a β-sheet structure. Thus, based on what was experimentally
observed, it might be concluded that EDTA does not modulate the structural properties of lin-SB056-1
in a significant manner, with the peptide killing bacteria through the formation of β-sheet on the
membrane surface. The observed increased activity of the peptide in the presence of EDTA might
be due to the ability of such chelator to sequester membrane-associated divalent cations, probably
synergizing with the peptide in perturbing membrane integrity and thus hastening bacterial demise.
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Another possibility can be envisaged. Given its inherent characteristics, infrared spectroscopy forces
one to work at high peptide/lipid ratio. It is possible that at lower peptide/lipid ratio, a condition
closer to reality, the effects of EDTA on the structural order of lin-SB056-1 could be considerably
stronger, possibly preventing the formation of extended β-sheets. This could be no detrimental to
peptide’s antimicrobial activity. On the contrary, it might help it, in analogy to what has been shown
in the case of Tachyplesin-I, a natural arginine-rich β-hairpin antimicrobial peptide for which the
formation of extended structures was considered responsible for the loss of peptide in-plane mobility
and consequently the reduction in peptide activity [43]. In the case of biofilms, this EDTA-peptide
interaction could even be relevant in favoring peptide’s mobility through the extracellular matrix.
It is well established that the preferred mode of growth of P. aeruginosa in CF lung is as biofilm,
a complex community that provides bacteria with a protective environment from the immune system
and antimicrobial treatment. At present, our weapons against biofilms are very limited and rely on early
aggressive treatment to prevent biofilm formation or administration of high doses of systemic/local
antibiotics in combinations to eradicate preformed biofilms. Once colonization with P. aeruginosa has
occurred and the organism has switched to the biofilm mode of growth, it is rare that it is eradicated
from the respiratory tract of patients with CF. Many AMPs have proven good activity against a
number of CF pathogens grown as biofilms [12]. Indeed, AMPs display several properties of an “ideal”
anti-biofilm agent including their activity against metabolically inactive or poorly active cells that
are abundant in biofilms, overcoming the limit of many traditional antibiotics that require actively
growing bacterial cells to act [13].
We have previously reported that the optimized lin-SB056-1 peptide is highly active in preventing
in vitro the formation of biofilms by P. aeruginosa [15]. In the present study, we sought to assess the
peptide’s activity against preformed biofilms (24 h-old) that are known to be much more refractory
than forming biofilms to treatment with antimicrobials including conventional antibiotics and AMPs.
In the case of AMPs, this is mainly attributed to the multiple interactions that they may establish
with the components of the biofilm extracellular matrix such as extracellular DNA, proteins and
polysaccharides [13]. These interactions may reduce the bioavailability of the peptides and lower
their anti-biofilm potential. In particular, P. aeruginosa secretes three types of exopolysaccharides, Pel,
Psl, and alginate, all of which play a role in the tolerance to antimicrobials when bacteria grow as
aggregates [44,45]. Thus, the use of disassembling agents is considered a good strategy to enhance
the therapeutic potential of AMPs and other antimicrobials against mature biofilms. A number of
compounds including lytic enzymes, furanones, triterpenes and D-amino acids have shown ability
to disassemble the biofilm structure [46–49]. In this study, we used as potentiating agent the cation
chelator EDTA. Unlike many other disassembling agents, EDTA is currently clinically approved for a
number of medical treatments including the therapy of lead poisoning, heavy metal detoxification
and hypercalcemia [19,50]. It has also proved to be safe and highly active when used in conjunction
with antifungal agents in a rodent model of invasive pulmonary aspergillosis [51] and to markedly
reduce the minimum inhibitory concentration of conventional antibiotics in a mouse model of lung
infection with mucoid P. aeruginosa [21]. When sub-inhibitory concentrations of lin-SB056-1 and EDTA
were combined together a net synergistic effect in the reduction of biofilm biomass of the non-mucoid
P. aeruginosa ATCC 27853 strain was observed. In agreement with previous studies, the observed
synergistic effect suggests that EDTA may lead to the breakdown of the biofilm by chelating divalent
metal ions, such as iron, calcium and magnesium, which have an important role in stabilizing the
biofilm extracellular matrix [19–21]. Such disassembling effect of EDTA may facilitate the diffusion
of the peptide through the biofilm layers. Interestingly, when EDTA was used alone against mature
biofilms of the mucoid strain PaM01, it exerted a highly significant antibiofilm activity at relatively
low concentrations and produced an additive effect in combination with the lin-SB056-1 peptide.
The susceptibility of PaM01 biofilms to EDTA is in agreement with previous studies that demonstrated
the ability of calcium not only to increase the thickness of biofilms of a mucoid strain of P. aeruginosa,
but also to play regulatory roles in bacterial gene expression [52]. For instance, calcium addition
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was reported to cause an eight-fold increase in alg gene expression in biofilms of a mucoid strain of
P. aeruginosa, and to induce the expression of other relevant bacterial virulence factors suggesting
that the chelating effect of EDTA may act at multiple levels against biofilms of mucoid strains of
P. aeruginosa. Furthermore, it has been demonstrated that the viscosity of alginate is determined largely
by its affinity for divalent cations, particularly calcium, which control the degree of cross-linking [18].
Thus, EDTA may increase the diffusion rates of lin-SB056-1 through the biofilm matrix by reducing
alginate viscosity.
An important aspect of the preclinical testing of AMPs as antimicrobial/antibiofilm agents is
the assessment of their activity in in vivo-like conditions as it is known that many AMPs are highly
or totally inhibited in such conditions. In particular, the CF airway environment is very selective
due to the presence of high concentrations of salts, mucin and DNA that may interfere with the
antimicrobial action of AMPs [53,54]. Therefore, to explore further the therapeutic potential of the
lin-SB056-1-EDTA combination, bactericidal assays were carried out in a previously described ASM
that closely mimics the CF sputum [5]. In this very complex medium, a strong synergistic bactericidal
effect of the combination was still observed against both the mucoid and non-mucoid strains of
planktonic P. aeruginosa. It is well known that EDTA has a detrimental effect on the outer membrane
permeability of Gram-negative bacteria [20]. By displacing divalent cations from their binding sites
in the lipopolysaccharide (LPS), EDTA may cause leakage of LPS, thus increasing the permeability
to lin-SB056-1 molecules and their interaction with the bacterial membranes. In addition, at least
part of the synergistic effect observed in ASM could be ascribed to the ability of EDTA to promote
the diffusion of the peptide in ASM, by reducing the viscosity of the sputum. This hypothesis is
supported by a recent study by Gustafsson and coworkers who demonstrated that CF intestinal mucus
can be transformed to an almost normal mucus in the presence of EDTA [55]. In particular, it has been
reported that at acidic pH and in the presence of calcium, the type II-mucin forms large aggregates that
are dissolved by removing calcium ions [55]. Thus, the chelating effect of EDTA could contribute to
reduce the viscosity of the ASM used in this study, which possesses a mild acidic pH (6.8) and contains
calcium at a concentration of approximately 10 mM as an element of casamino hydrolysate used as a
source of amino acids [56].
In chronically infected lungs of CF patients, P. aeruginosa persists in the form of antibiotic-tolerant
bacterial aggregates floating in the airways mucus and exhibiting a phenotype closely resembling
that of surface-attached biofilms [57]. It has been demonstrated that in microaerobic conditions
ASM supports the formation of BLSs similar to the bacterial aggregates described within the CF
airways [5,8,54]. Thus, we sought to investigate the effect of our peptide/EDTA combination on
the formation of BLSs by the P. aeruginosa ATCC 27853 strain in ASM. Interestingly, an almost total
inhibition of BLSs formation was observed during the entire observational period (three days). In the
first 24 h of incubation, inhibition of BLSs formation correlated with a sharp reduction in viable count.
As high inoculum (107–108 CFU/mL) of stationary phase bacteria are needed to allow BLSs formation
in ASM [5,58], the killing effect exerted by the combination at 24 h may have contributed to keep the cell
density at low levels, impeding BLSs formation at this time point. At later time points, a progressive
increase in cell number was observed suggesting an administration regiment every 24 h. Nevertheless,
despite the increment in cell number, the BLS count remained low up to 72 h, suggesting that the
lin-SB056-1 peptide and/or EDTA may somehow interfere with the phenomenon of cell aggregation,
by directly interacting with bacterial cells and/or by sequestering medium components essential for
biofilm formation [59].
Despite our attempts, we were not able to obtain BLSs of the mucoid strain PaM01 in ASM in
agreement with previous reports that demonstrated that P. aeruginosa strains may greatly differ in their
ability to produce BLSs in such a medium [5]. Nevertheless, the results obtained with the ATCC 27853
strain suggest that the lin-SB056-1/EDTA combination may impede the formation of BLSs in conditions
very relevant to the CF environment. As BLSs formation is believed one of the major obstacles to the
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success of the therapy, ability of the combination to maintain bacterial cells in a planktonic status could
render them more susceptible to the action of antimicrobial drugs.
It is noteworthy that both lin-SB056-1 and EDTA at the concentrations used in this study
(12.5/25 µg/mL lin-SB056-1, and 1.25 mM EDTA) did not result hemolytic towards human erythrocytes
in previous studies [15,60] further highlighting the therapeutic potential of the peptide.
4. Materials and Methods
4.1. Pseudomonas aeruginosa Strains and Culture Conditions
P. aeruginosa strains were isolated from sputum of CF patients at the Microbiology Unit of the
University Hospital of Pisa, Italy. MALDI-TOF (Bruker Daltonics, Bremen, Germany) was used for
the identification of the bacterial species and VITEK® 2 system (bioMérieux, Bagno a Ripoli, Italy)
for the definition of the antimicrobial susceptibility profile, according to The European Committee
on Antimicrobial Susceptibility Testing (EUCAST Clinical Breakpoints http://http://www.eucast.
org/clinical_breakpoints/). Five clinical isolates of P. aeruginosa (PaNM01, PaNM02, PaM01, PaM02,
and PaM03) and the reference strain P. aeruginosa ATCC 27853 were used in the study. P. aeruginosa
strains were qualitatively evaluated regarding their ability to express a mucoid phenotype. To this aim,
bacterial suspensions were streaked onto the surface of MacConkey agar (bioMérieux, Marcy-l′Étoile,
France) and Cetrimide agar (Sigma-Aldrich, St. Louis, MO, USA) plates and incubated at 37 ◦C for 48 h.
The development of colonies with a slimy phenotype was rated as positive for the presence of mucoid,
alginate-producing cells. The strains were grown with shaking in TSB (Oxoid, Basingstoke, UK) or in
Luria Bertani broth (LB) at 37 ◦C for liquid cultures and on Tryptone soy agar (TSA) (Oxoid, Hampshire,
UK) for 48 h at 37 ◦C for CFU determination.
4.2. Peptide and EDTA Solutions
Lin-SB056-1 peptide (KWKIRVRLSA) was purchased from Peptide Protein Research, Ltd.
(Fareham, UK) with a purity of 98%; it was provided as chloride salt and used without further
purification. Peptide [KIGAKI]3, HCl salt, 95% purity with C-terminus amidated was kindly provided
by Prof. Anne S. Ulrich and Dr. Parvesh Wadhwani from the Karlsruhe Institute of Technology
(Karlsruhe, Germany). EDTA was obtained from Sigma-Aldrich. A stock EDTA solution (0.5 M)
was prepared in milli-Q water and the pH of the solution was adjusted to 8.0 with NaOH. The stock
solution was then diluted in milli-Q water to obtain a working solution of 50 mM that was sterilized
by filtration and stored at 4 ◦C.
4.3. Infrared Spectroscopy
Lin-SB056-1 was studied in three different media with D2O as solvent, namely, (i) phosphate
buffer (PB; potassium H2PO4/HPO4; 10 mM total phosphates; pH 7.4); (ii) phosphate buffer
saline (PBS; prepared from PB with 150 mM NaCl) and (iii) PBS with Na-EDTA (PBSE; prepared
from PBS with [EDTA]/[peptide] molar ratio of 3:1). Peptide was dissolved at 2.0 mM in the
presence of 20 mM large unilamellar vesicles (LUVs). The latter were prepared from a mixture
of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC) and POPG by the extrusion method,
as described in details elsewhere [61]. The [POPC]/[POPG] molar ratio was always 3:1, but, in the
case of PBS, experiments were also performed with LUVs prepared with [POPC]/[POPG] ratio of 1:3.
Model peptide KIGAKI (whose sequence is [KIGAKI]3) was employed as reference for β-sheets [29].
All infrared spectra were acquired with a Bruker Vector-22 equipped with a diamond single-reflection
Attenuated Total Reflection accessory (Platinum ATR module) and a liquid nitrogen cooled MCT
detector. The software OPUS (version 6.5, Bruker) was used for both spectra acquisition and data
analysis. Spectra were acquired from 10 µL of the sample deposited on the ATR crystal. These FH
samples were acquired in the 3500–600 cm−1 spectral range, with 4 cm−1 resolution, by applying
automatic atmosphere compensation and 32 scans. Background of the clean ATR crystal was acquired
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with the same parameters immediately before each measurement. Spectrum of buffers was also
acquired in the same experimental conditions to be subtracted from samples’ spectra. Spectra were
also recorded from the same samples as RF, obtained by depositing 10 µL of the dispersion on the
ATR crystal and by gently evaporating the solvent under a stream of nitrogen. Rehydration was
achieved by placing a small Petri dish over the film after deposition of several drops of D2O around
the crystal. Spectra acquisition was started after one minute. Acquisition parameters were the same as
for FH samples but 16 scans were acquired for the RF ones. The spectrum of the corresponding LUVs
rehydrated film was acquired to be used for both medium and vesicles signals removal.
4.4. Bactericidal Activity in Sodium-Phosphate Buffer (SPB)
The bactericidal activity of lin-SB056-1 against P. aeruginosa strains was evaluated in
sodium-phosphate buffer (SPB) 10 mM, pH 7.4 supplemented with 1% TSB (SPB/TSB) by the
microdilution method. To this aim, bacterial strains were grown in TSB until exponential phase,
washed by centrifugation and resuspended in SPB to reach a density of 1 × 107 CFU/mL. Bacteria,
contained in a volume of 10 µL, were added to 90 µL of SPB/TSB containing the peptides at different
concentrations (ranging from 0.78 to 12.5 µg/mL). To check for cell viability, samples containing
bacteria suspended in SPB/TSB in the absence of the peptide were established. After an incubation at
37 ◦C with shaking for various time intervals (5, 15, 30, and 90 min), the samples were diluted 10-fold
in TSB and plated on TSA for CFU counting. The MBC was defined as the minimal concentration of
the peptide causing a reduction of at least 3-log in the number of CFUs after 90 min of incubation. In a
set of experiments, peptide’s activity was assessed at 1.5 and 24 h in the presence of serum by adding
heat inactivated pooled human serum, obtained from 6 healthy blood donors, to the assay mixture to
reach a final serum concentration of 12.5%.
4.5. Biofilm Treatment Assays
P. aeruginosa ATCC 27853 and the mucoid strain PaM01 were cultured overnight in TSB at 37 ◦C
with agitation. After diluting bacterial suspensions 1:100 in TSB, aliquots of 100 µL were seeded into
wells of flat-bottom polystyrene 96-well microtiter plates (Corning Costar, Lowell, MA, USA). Biofilms
were left to form for 24 h (ATCC 27853 strain) or 7 days (PaM01 strain) at 37 ◦C in the absence of
antimicrobial compounds. Previously it has been demonstrated that mucoid strains of P. aeruginosa
need a supplement of calcium to produce appreciable amount of biofilm in vitro [52]. In agreement
with this observation, in our hands the PaM01 strain was unable to form biofilm in the absence of
calcium. Therefore, the medium of this strain was enriched with 0.5 mM calcium chloride to allow
the formation of biofilms. Established biofilms were then washed three times with SPB in order to
remove non-adherent cells, and exposed in fresh medium (TSB diluted 1:1 with SPB) to different
concentrations of lin-SB056-1 (from 6.25 to 50 µg/mL) alone and in combination with EDTA (from 0.3
to 2.5 mM). Wells added with EDTA only were also established. In the case of the strain PaM01, the
medium was enriched with 0.25 mM calcium chloride. Microplates were incubated statically at 37 ◦C
for 24 h. Following incubation, the biofilm biomass was determined by crystal violet staining. After
24 h incubation bacterial biofilms were washed twice with 200 µL of PBS and incubated at 60 ◦C for
60 min to dry. The wells were then stained at room temperature with 150 µL of 1% crystal violet in 7%
ethyl alcohol solution for 10 min. The plates were then washed with 200 µL of sterile distilled water
and air-dried at 37 ◦C for 30 min. To dissolve the dye associated with attached biofilm, 200 µL of 30%
acetic acid were added to the wells and the OD570 absorbance was measured on a microplate reader
(Bio-Rad Laboratories, Segrate, Italy).
4.6. Bactericidal Assays in ASM
For ASM preparation, the components were dissolved into sterile water at the following
concentrations: mucin (Sigma-Aldrich), 0.5% (w/v); unsheared salmon sperm DNA (Sigma-Aldrich),
0.4% (w/v); NaCl, 0.5% (w/v); KCl, 0.2% (w/v); casamino acids (Oxoid), 0.5% (w/v); egg yolk emulsion
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(0.15%, source of lecithin; sterile; Sigma-Aldrich). After each addition, the mixture was vigorously
vortexed. The pH of the solution was adjusted at 6.8 with Tris-HCl 1 M, pH 8.5 [5]. P. aeruginosa was
grown overnight in LB broth, pelleted, washed with PBS, and resuspended in ASM at a density of
106 CFU/mL. A volume of 10 µL of the peptide (3.12 to 25 µg/mL) and/or 10 µL of EDTA (0.62 to
2.5 mM) were added to 80 µL of ASM containing bacteria. To check for cell viability, bacteria were
suspended in ASM 80% alone. After an incubation at 37 ◦C with shaking for 90 min (or 24 h), the
samples were diluted 10-fold in TSB and plated on TSA, to determine the number of viable cells.
4.7. Static Culture System for the Development of Biofilm-Like Structures (BLSs) in ASM
For the development of BLSs, P. aeruginosa ATCC 27853 was grown overnight in LB broth and
then diluted into ASM to a final cell density of 107 CFU/mL. Bacteria were dispensed into 96-well
microplate in the presence of lin-SB056-1 or EDTA alone or in combination. The plates were incubated
at 37 ◦C in static (non-shaking) conditions under microaerophilic conditions for different time intervals
before assessing BLS formation. To this aim, 40 µL of each bacterial suspension was gently transferred
onto a glass slide, covered with a coverslip and observed under light microscope (see Section 4.8).
At each incubation time, an aliquot of the samples was vigorously vortexed to disassemble the BLSs,
subsequently diluted 10-fold in TSB, and plated on TSA for the enumeration of the CFU.
4.8. Visualization and Quantification of BLSs
BLSs were examined under an Olympus BX40 microscope with a 40× or 100× oil immersion
objective and photographed using Olympus C-5060 camera. BLSs were quantified based on their size in
50 randomly selected microscope fields. Two different operators performed the analysis independently.
The size of each BLS was evaluated by establishing a scoring based on the area of the microscope field
occupied by the aggregate (1/4, 1/2, 3/4, 1 field). BLS content of a sample was determined dividing
the sum of the score values by the number of microscope fields analyzed (i.e., 50) and expressed
in percent.
4.9. Statistical Analysis
All statistical analyses were performed using one-way ANOVA followed by Tukey–Kramer
post-hoc test. A p-value less than 0.05 was considered statistically significant. The data are
means ± error standard of the mean (SEM) of three independent experiments.
5. Conclusions
Overall, the in vitro data obtained in this study demonstrated that the AMP lin-SB056-1 displays
a very strong and rapid bactericidal activity against both mucoid and non-mucoid strains of
P. aeruginosa. The combination of lin-SB056-1 with EDTA results in a potentiated antibiofilm effect
against P. aeruginosa mature biofilms. The enhancement of the antibiofilm activity could be due to the
destabilizing action of EDTA on the biofilm matrix as well as to a direct effect on biofilm-embedded
cells. Importantly, in culture conditions mimicking the CF sputum, the combination lin-SB056-1/EDTA
showed a significant bactericidal effect towards planktonic cells of P. aeruginosa and ability to almost
completely inhibit the formation of BLS over a 72 h time-span. Future in vivo studies are planned
to fully assess the therapeutic potential of the lin-SB056-1/EDTA combination in the therapy of
P. aeruginosa infections in CF patients.
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AMP Antimicrobial peptide
ANOVA Analysis of variance
ASM Artificial sputum medium
BLS Biofilm-like structure
CF Cystic fibrosis
CFU Colony-forming units
EDTA Ethylenediaminetetraacetic acid
FH Fully hydrated
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LPS Lipopolysaccharide
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MBC Minimum bactericidal concentration
MDR Multi-drug resistant
PB Phosphate buffer
PBS Phosphate buffered saline
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